To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
Clinical trial NCT04661007 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04661007
- Sponsor
- Incyte Biosciences Japan GK
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-15
- Primary completion
- 2025-07-01
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.